Having peaked in 2021 and plummeted as the pandemic ended, deal value revived in 2023, with pharma companies pursuing growth and medtech companies chasing profitability. These trends promise to continue in 2024.
Click here to read the entire article
Having peaked in 2021 and plummeted as the pandemic ended, deal value revived in 2023, with pharma companies pursuing growth and medtech companies chasing profitability. These trends promise to continue in 2024.
Click here to read the entire article